NCT06836037View on ClinicalTrials.gov

A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 5, 2022

Primary Completion Date

February 2, 2023

Study Completion Date

February 2, 2023

Conditions
Healthy
Interventions
DRUG

Efinopegdutide

Subcutaneous injection

DRUG

Placebo

placebo matching efinopegdutide

Trial Locations (1)

200032

Zhongshan Hospital,Fudan University-Dep. of Clinical Pharmacology (Site 0001), Shanghai

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY